MERCK & CO., INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 100.98 USD | +1.74% |
|
+1.26% | +1.51% |
| 01:30am | Merck & Co., Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 04:30 PM | |
| Jan. 13 | GSK Acquiring US-Based IDRx for up to $1.15 Billion | MT |
Company Valuation: Merck & Co., Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 231,557 | 206,957 | 193,588 | 281,302 | 276,259 | 255,443 | 255,443 | - |
| Change | - | -10.62% | -6.46% | 45.31% | -1.79% | -7.54% | 0% | - |
| Enterprise Value (EV) 1 | 247,453 | 230,686 | 218,594 | 298,801 | 304,221 | 278,205 | 265,442 | 251,817 |
| Change | - | -6.78% | -5.24% | 36.69% | 1.81% | -8.55% | -4.59% | -5.13% |
| P/E ratio | 23.9x | 29.4x | 14.9x | 19.4x | 779x | 14.3x | 11.4x | 10.4x |
| PBR | 9x | 8.18x | 5.07x | 6.12x | 7.34x | 5.41x | 4.29x | 3.46x |
| PEG | - | -1.1x | 0.2x | 1.7x | -8x | 0x | 0.5x | 1.09x |
| Capitalization / Revenue | 4.94x | 4.31x | 3.97x | 4.75x | 4.6x | 3.99x | 3.79x | 3.58x |
| EV / Revenue | 5.28x | 4.81x | 4.49x | 5.04x | 5.06x | 4.35x | 3.94x | 3.53x |
| EV / EBITDA | 12.6x | 11.2x | 10.5x | 11.3x | 30.2x | 10.4x | 8.42x | 7.44x |
| EV / EBIT | 15.5x | 13.6x | 12.4x | 13.3x | 49x | 11.8x | 9.45x | 8.19x |
| EV / FCF | 24.8x | 41.4x | 25.2x | 20.3x | 33.3x | 15.1x | 11.5x | 10.1x |
| FCF Yield | 4.03% | 2.41% | 3.97% | 4.92% | 3.01% | 6.62% | 8.7% | 9.88% |
| Dividend per Share 2 | 2.26 | 2.48 | 2.64 | 2.8 | 2.96 | 3.05 | 3.202 | 3.332 |
| Rate of return | 2.48% | 3.03% | 3.44% | 2.52% | 2.72% | 3.02% | 3.17% | 3.3% |
| EPS 2 | 3.81 | 2.78 | 5.14 | 5.71 | 0.14 | 7.077 | 8.831 | 9.677 |
| Distribution rate | 59.3% | 89.2% | 51.4% | 49% | 2,114% | 43.1% | 36.3% | 34.4% |
| Net sales 1 | 46,840 | 47,994 | 48,704 | 59,283 | 60,115 | 63,991 | 67,424 | 71,350 |
| EBITDA 1 | 19,572 | 20,570 | 20,910 | 26,431 | 10,083 | 26,832 | 31,511 | 33,852 |
| EBIT 1 | 15,920 | 16,945 | 17,696 | 22,522 | 6,211 | 23,622 | 28,098 | 30,741 |
| Net income 1 | 9,843 | 7,067 | 13,049 | 14,519 | 365 | 17,682 | 22,060 | 24,521 |
| Net Debt 1 | 15,896 | 23,729 | 25,006 | 17,499 | 27,962 | 22,763 | 9,999 | -3,625 |
| Reference price 2 | 90.95 | 81.80 | 76.64 | 110.95 | 109.02 | 100.98 | 100.98 | 100.98 |
| Nbr of stocks (in thousands) | 2,545,984 | 2,530,034 | 2,525,944 | 2,535,396 | 2,534,023 | 2,529,636 | 2,529,636 | - |
| Announcement Date | 2/5/20 | 2/4/21 | 2/3/22 | 2/2/23 | 2/1/24 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E ratio (Y) | EV / Sales | EV / EBITDA | Yield (Y) | Capi. ($) | ||
|---|---|---|---|---|---|---|
| 14.02x | 4.28x | 10.21x | +3.07% | 255B | ||
| 63.2x | 16.3x | 46.04x | +0.65% | 718B | ||
| 28.25x | 10.01x | 20.16x | +1.73% | 373B | ||
| 20.53x | 3.99x | 11.63x | +3.33% | 348B | ||
| 38.24x | 6.54x | 14.3x | +3.55% | 312B | ||
| 15.89x | 3.78x | 9.87x | +3.69% | 232B | ||
| 24.21x | 4.33x | 13.45x | +2.32% | 204B | ||
| 18.01x | 4.2x | 10.7x | +3.83% | 197B | ||
| 15.69x | 3.33x | 8.28x | +6.24% | 152B | ||
| 28.71x | 5.74x | 10.1x | +3.45% | 145B | ||
| Average | 26.67x | 6.25x | 15.47x | +3.18% | 293.65B | |
| Weighted average by Cap. | 33.14x | 8.13x | 20.96x | +2.62% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- MRK Stock
- Valuation Merck & Co., Inc.